Acasti Pharma (ACST): רווח נקי למניה ב-12 החודשים האחרונים

Acasti Pharma (ACST) is implementing unique platforms to combat rare neuromuscular pain while avoiding price wars. Protection against replication is ensured by FDA orphan drug status. Net income per share on a rolling year basis visualizes this foundation, where the -1.21 metric reflects current dynamics. Global sales of patented medications guarantee the company high scalability of its intellectual capital.

This trailing twelve-month earnings per share snapshot reflects the status of Acasti Pharma (ACST) as a biopharmaceutical startup. The eps_ttm_co metric aggregates annual net income divided by the number of shares, neutralizing short-term market noise. The current value of -1.21 demonstrates high sensitivity to R&D expenditures. Negative momentum confirms a dependence on Phase 3 clinical trial outcomes. Regular secondary offerings dilute equity, reducing the fundamental stability of the company's position.